Video

Module 4: Integrating Novel Therapies in Breast Cancer Management

Release Date

September 30, 2026

Expiration Date

October 1, 2027

Credits

3.25 CME, NCPD

Activity Overview

This educational activity is an archive of the live conference held on July 17-18, 2026.

Target Audience

This educational activity is intended for medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

  • Integrate genomic and molecular biomarker findings into individualized treatment strategies for patients with early-stage and metastatic breast cancer
  • Evaluate emerging data from key clinical trials and their implications for the management of early-stage and advanced/metastatic breast cancer
  • Apply current evidence and guideline recommendations to develop stage-specific, personalized treatment plans for patients with breast cancer
  • Implement evidence-based strategies to prevent and manage treatment-related adverse events in breast cancer care
Module 4: Integrating Novel Therapies in Breast Cancer Management

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 3.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Exact Sciences Corporation; Hologic, Inc; Novartis Pharmaceuticals Corporation; Puma Biotechnology, Inc; Stemline Therapeutics, Inc; and Tolmar Pharmaceuticals.

Follow Us on Social Media!

You Also Might Like...

Course

Module 4: Integrating Novel Therapies in Breast Cancer Management

Create Account